National Institute of Dental and Craniofacial Research (NIDCR)

91 total trials 11 currently recruiting 70 completed

National Institute of Dental and Craniofacial Research (NIDCR) sponsors 91 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 70 completed. 2 of these trials are in Phase 3-4 (later-stage) and 41 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sjogren's Syndrome, with 6 trials.

Trial Pipeline

91 total, page 2 of 2

COMPLETED Phase 2

Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

NCT00026819

COMPLETED

Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells

NCT00023491

COMPLETED Phase 3

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

NCT00017927

COMPLETED

Pain Evaluation and Treatment

NCT00362167

COMPLETED Phase 2

Topiramate in the Treatment of Sciatica

NCT00011804

COMPLETED Phase 2

Pain Treatment for Sciatica

NCT00009672

COMPLETED Phase 2

Capsaicin to Control Pain Following Third Molar Extraction

NCT00008476

COMPLETED

Pathophysiology of Chronic Wounds

NCT00006437

COMPLETED Phase 1

Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome

NCT00006174

COMPLETED

Cyclooxygenase Levels Following Surgery to Remove Third Molars (Wisdom Teeth)

NCT00006175

COMPLETED Phase 2

Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction

NCT00006070

COMPLETED

Oral Manifestations of Aplastic Anemia

NCT00006300

COMPLETED Phase 1

Effects of Topical SLPI on Skin Wounds

NCT00005569

COMPLETED Phase 2

Influence of Genetics in Pain Sensitivity

NCT00001956

COMPLETED

Eligibility Screening for National Institute of Dental and Craniofacial Research Studies

NCT00001983

COMPLETED Phase 2

Etanercept Therapy for Sjogren's Syndrome

NCT00001954

COMPLETED Phase 2

Celebrex for Pain Relief After Oral Surgery

NCT00006299

COMPLETED Phase 2

Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)

NCT00001955

COMPLETED

The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers

NCT00001953

COMPLETED

Using a Narcotic to Enhance the Numbing Effect of the Local Anesthetic Lidocaine on Inflamed Molar Teeth

NCT00001952

COMPLETED

Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

NCT00001852

COMPLETED

Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome

NCT00001851

COMPLETED Phase 2

Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome

NCT00001728

COMPLETED

Study of the Composition of Dental Plaque

NCT00001726

COMPLETED Phase 2

Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain

NCT00001725

COMPLETED Phase 2

Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction

NCT00001724

COMPLETED NA

Evaluation and Treatment of Oral Soft Tissue Diseases

NCT00001601

COMPLETED

Diagnosis and Evaluation of Patients Needing Third Molar (Wisdom Tooth) Extraction and Patients With Chronic Facial Pain

NCT00001600

COMPLETED Phase 2

Pilot Study of Thalidomide to Treat Sjogren's Syndrome

NCT00001599

COMPLETED Phase 2

DHEA Treatment for Sjogren's Syndrome

NCT00001598

COMPLETED

Pain Measurement in Healthy Volunteers

NCT00001597

COMPLETED

Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome

NCT00001973

COMPLETED Phase 2

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

NCT00001524

COMPLETED

Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation

NCT00001523

COMPLETED

Bone Regeneration Using Bone Marrow Stromal Cells

NCT00001391

COMPLETED

Salivary Evaluation in Healthy Volunteers

NCT00001390

COMPLETED Phase 2

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344

COMPLETED

Positron Emission Tomography to Measure Pain and Pain Control

NCT00001307

COMPLETED

Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects

NCT00001211

TERMINATED

Evaluation of Salivary Gland Dysfunction

NCT00001196

COMPLETED NA

Evaluation of Patients With Unusual Diagnostic or Treatment Considerations

NCT00001182

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 32
Phase 3 2

What the Pipeline for National Institute of Dental and Craniofacial Research (NIDCR) Shows

According to the ClinicalTrials.gov registry, National Institute of Dental and Craniofacial Research (NIDCR) is linked to 91 US clinical trials across every stage of research activity. Of those, 11 studies are currently recruiting, about 12% of the sponsor's indexed portfolio, and 70 are already marked complete, representing roughly 77% of the total.

The phase mix for National Institute of Dental and Craniofacial Research (NIDCR) reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 41 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for National Institute of Dental and Craniofacial Research (NIDCR) is Sjogren's Syndrome with 6 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.